Tue, Sep 23, 2014, 11:19 AM EDT - U.S. Markets close in 4 hrs 41 mins


% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • karenyao07 karenyao07 Apr 11, 2013 1:45 AM Flag

    good news for those bought at $1-$2 but bad news for those bought at $20+

    Now the stock is less risk and less award.

    1. With Takeda taking full responsibility for OMONTYS, the drug will be back to market at very very chance (Note: a proved drug with 99.8% effective already). It is much less risk and the stock price should be $2-$3 before re-introducing and $5-$15 after re-introducing.

    2. Because Takeda receives a worldwide, exclusive royalty-bearing license under Affymax and joint Takeda-Affymax patents to develop, manufacture and commercialize OMONTYS, Affymax get less profit after re-introducing. The stock price won't reach $25-$80 range.

    3. Takeda may know the root-cause already but want to fully control OMONTYS and Affymax may ...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Dude, they sold the company's only product for $20 million plus royalties. How is this not a 50-cent stock?

    • Basically this 8-k puts a roof to this company... especially to this stock.
      Says: "worths no more than 180 Mil$".
      Actually until yesterday, there was no roof! That's the worst point.

      Then add up 50Mil$ cash..... but subtract AFFY admin costs until sales will get in Takeda.... subtract sueing costs from the 3 patients and from investors lawsuits.

      IMO, Mcap won't go over 100Mil$.
      The only way to create new value for this company is buying another drug and developing it.... but takes a decade and money.

      My personal compliments to the CEO who sold his soul for a new shining chair, I guess.
      A multi-bil$ drug...... sold for 180Mil$...... great manager action.

0.15-0.01(-6.25%)10:45 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.